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Abstract In pregnant women with heart disease, complica-
tions can arise due to the haemodynamic burden of preg-
nancy and to hypercoagulation. Most problems can be
managed medically, but sometimes cardiac surgery or per-
cutaneous intervention is unavoidable. Cardiac surgery has
similar maternal mortality to that outside pregnancy, but
foetal mortality and morbidity are considerable. Measures
to reduce the risk by adaptation of the management of
cardiopulmonary bypass are described. When gestational
age is >28 weeks, pre-surgery delivery of the foetus should
be considered. Percutaneous intervention exposes the foetus
to radiation. The radiation dose for common cardiac proce-
dures, however, does not result in detectable harmful foetal
effects.
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Introduction
Heart disease is an increasingly important cause of maternal
morbidity and mortality during pregnancy. Most cardiac
problems that arise in pregnant women with heart disease
can be managed without interventional procedures. Howev-
er, the haemodynamic changes of pregnancy (increase in
circulating volume and cardiac output, decrease in vascular
resistance, and hypercoagulation) may sometimes lead to
deterioration in previously stable women. Indications for
intervention may arise when cardiac conditions worsen dur-
ing pregnancy (such as rapid progression of aortic dilatation
in Marfan syndrome), when the severity of the disease was
undiagnosed or underestimated before pregnancy (which is
often the case in mitral stenosis), or when new complica-
tions or diagnoses arise (for example prosthetic valve throm-
bosis, endocarditis or myocardial infarction)[1].
This special article reviews the indications, timing, ma-
ternal and foetal risk and management of cardiac surgery as
well as of catheter interventions in pregnant women with
heart disease.
Indications for intervention during pregnancy
Maternal mortality associated with cardiac surgery is rela-
tively high (6%). This is probably caused by the urgent
character of the procedure and mortality is not different from
that in non-pregnant women undergoing similar emergency
procedures [1–3]. However, because the risk of foetal loss
and late morbidity for the child is considerable, cardiac
surgery should only be performed when medical therapy
or interventional procedures fail and the mother’sl i f ei s
threatened. Percutaneous intervention exposes the foetus to
the risk of radiation. The risk is limited for most procedures,
but percutaneous intervention should only be performed
when there are no medical therapeutic options. Since the
risk for the foetus is lower than the risk of cardiac surgery,
percutaneous intervention is preferred when possible [2].
Valvular heart disease
Mitral stenosis is a frequent diagnosis in immigrants and
is still prevalent in developing countries. Mitral stenosis
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pregnancy intervention is recommended when the valve
area is <1.5 cm
2. When pulmonary oedema or pulmo-
nary hypertension develop during pregnancy, therapy
with β-blockers and diuretics is indicated. When, de-
spite optimal medical therapy, the woman remains in
NYHA class III/IV or systolic pulmonary artery pressure
remains >50 mmHg, percutaneous intervention can be
considered. Since a short radiation time is important the
procedure should be performed by an experienced oper-
ator. Abdominal shielding is advised [1, 2].
Aortic stenosis in young women of fertile age is
usually caused by congenital valve malformation. Wom-
en with aortic stenosis are at increased risk of cardiac
and obstetric complications [4–6]. Heart failure, arrhyth-
mias and hypertensive disorders are the most frequent
complications. The complication rate is associated with
stenosis severity [4, 6]. Previously, pre-pregnancy inter-
vention was advocated in all women with severe aortic
stenosis [7]. However, although clinical deterioration
during pregnancy in women with severe aortic stenosis
has been described, the risk of mortality is very low
according to recent series [2, 8, 9]. When women with
severe aortic stenosis contemplate pregnancy, the risk of
pregnancy should be weighed against the risk of pre-
pregnancy surgical treatment. Biological valves have a
high deterioration rate and will inevitably result in
eventual re-operation, while mechanical valves are asso-
ciated with a high risk of severe maternal complications
[2, 7, 10]. Therefore, according to the most recent
European Society of Cardiology guidelines, pre-
pregnancy intervention is only advised in women with
severe aortic stenosis and symptoms, an abnormal exer-
cise test or left ventricular dysfunction, [2]. When a
woman with severe aortic stenosis deteriorates during
pregnancy and medical therapy fails, balloon valvulo-
plasty by an experienced operator may be a suitable
option in non-calcified valves. Even in calcified valves,
balloon valvuloplasty, although not without risk, may be
a safer option than surgery, and it may serve as a bridge
to surgery after delivery. However, in some cases sur-
gery may be unavoidable[1, 2].
Regurgitant lesions, although not innocent, are better
tolerated than stenotic lesions and rarely require intervention
during pregnancy [4, 8].
Mechanical prosthetic valves may require surgery during
pregnancy since the risk of valve thrombosis is considerable
[2, 4, 10, 11].
Aortic disease
Aortic pathology was the second cardiovascular cause of
maternal mortality in the UK in the most recent report
on maternal mortality [12]. Progressive aortic dilatation
and aortic dissection are mainly observed in women
with Marfan syndrome, Ehlers-Danlos syndrome, Turner
syndrome and bicuspid aortic valve. The European So-
ciety of Cardiology guidelines recommend pre-
pregnancy surgery in women with Marfan syndrome or
bicuspid aortic valve when the aortic diameter is >
45 mm and >50 mm, respectively. During pregnancy,
prophylactic surgery should be considered when the
aortic diameter is >50 mm and increasing rapidly. When
aortic dissection occurs during pregnancy, surgery
should be performed. When the foetus is viable, caesar-
ean section is recommended immediately before cardiac
surgery [2].
Ischaemic heart disease
Ischaemic heart disease is increasingly encountered dur-
ing pregnancy due to delay of pregnancy to older age
and unhealthy lifestyle. It is an important cause of
maternal mortality [12]. In a recent review comprising
103 pregnant women with acute myocardial infarction,
maternal mortality was 11%. Atherosclerosis was the
underlying cause in 40% of infarctions. Coronary dis-
section occurs more often than outside pregnancy and
was responsible for 27% of the cases in this series [13].
Percutaneous coronary intervention has now been
reported in more than 200 cases. In women with ST-
elevation myocardial infarction, it is the reperfusion
therapy of choice. Experience with thrombolysis is lim-
ited during pregnancy, but it carries the risk of subpla-
cental bleeding. Thrombolysis is also contraindicated
because there is a high risk of coronary artery dissection
as the underlying mechanism of the infarction [1, 2].
Percutaneous intervention has reduced the necessity for
coronary artery bypass grafting during pregnancy, which
is now extremely rare [1]. The risks for the foetus
resulting from radiation exposure are limited but should
be taken into account. Bare metal stents are preferred
during pregnancy, because the safety of drug-eluting
stents is unknown. The need for prolonged dual anti-
platelet therapy after placement of drug-eluting stents is
a concern [2].
Cardiopulmonary bypass during pregnancy
Cardiopulmonary bypass during pregnancy is associated
with similar maternal mortality to that outside pregnan-
cy [2, 3]. However, the foetal mortality rate is 14 to
33% [1, 3, 14]. Sustained uterine contractions resulting
in uteroplacental hypoperfusion and foetal hypoxia are
considered the most important cause of foetal death
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modilution, causing dilution of progesterone, as well as
cooling and rewarming. Nonpulsatile flow triggers va-
soconstriction, further increasing placental dysfunction
[14]. Uteroplacental flow is further compromised by
decrease in maternal blood pressure. Foetal bradycardia
is often observed. Although the mechanism of this bra-
dycardia is not known, foetal hypoxia due to haemodi-
lution and to uteroplacental hypoperfusion probably
plays a role [14]. In addition to foetal mortality, signif-
icant morbidity including late neurological impairment
has been described, mainly associated with premature
birth [2, 3]. Because of these risks, cardiac surgery
should be avoided whenever possible. In the first tri-
mester the risk of foetal malformations is higher, there-
fore postponement of cardiac surgery until after the 13th
week of gestation is preferred. It is recommended to
monitor uterine contractions and foetal heart rate during
surgery. To diminish the risk of foetal bradycardia and
uterine contractions, the European Society of Cardiology
guidelines recommend to minimise cardiopulmonary by-
pass time and to maintain a pump flow >2.5 l/min/m
2,a
perfusion pressure >70 mm Hg, a maternal haematocrit
>28%, and to use pulsatile flow and normothermic
perfusion [2]. Additionally a left lateral tilt of 15º is
recommendable to relieve pressure of the uterus on the
caval vein.
Because of the high foetal risk, when gestational age
is advanced, it should be considered to deliver the baby
before cardiac surgery. However, it is a matter of debate
at which gestational age pre-surgery delivery is advan-
tageous for the foetus, since premature birth is in itself
associated with foetal mortality and morbidity. Although
the prognosis of very premature babies has improved in
recent years, before 26 weeks of gestation neonatal
mortality is around 40% and delivery before surgery is
not recommended. After 28 weeks of gestation, neonatal
mortality is<10% and severe morbidity is limited; there-
fore, the guidelines recommend that delivery before
cardiopulmonary bypass should be considered. If possi-
ble the surgery should be delayed until a full course of
corticosteroids (at least 24 h) has been administered to
the mother, since this improves foetal outcome consid-
erably [2]. Between 26 and 28 weeks the prognosis of
the baby depends on gender, estimated birth weight, the
presence of foetal malformations, and the administration
of corticosteroids. Additionally the experience of the
local neonatal unit is important in the decision whether
or not to perform a caesarean section before cardiopul-
monary bypass. The decision should be made on an
individual basis [2]. It should be kept in mind that
maternal prognosis may be negatively influenced by
surgery shortly after delivery, therefore delivery should
only be performed when the advantages for the baby are
clear [15].
Percutaneous interventions during pregnancy
Whenpregnantwomenare exposedtodiagnosticortherapeutic
procedures involving radiation, this may cause high levels of
anxiety, both among the health care providers and the women.
This sometimes results in termination of pregnancy. Indeed,
ionising radiation can have harmful effects, which are cell
death and teratogenic effects, carcinogenesis and genetic
effects (mutations)[16]. These effects are, however, not ob-
served with the doses that are needed for the majority of
diagnosticandtherapeuticprocedures.There isconsensusthat
the risks for the foetus are very limited when the dose to the
mother is <50 mGy [2, 16]. With doses below this level, there
is no observed increased risk of foetal malformations. Avery
small increase in the risk of childhood cancer cannot be ruled
out. The most frequently performed cardiac percutaneous
interventions during pregnancy are mitral balloon valvulo-
plasty and coronary angioplasty. Radiation doses to the moth-
er for such procedures are<20 mGy. The foetal risk is limited
further because the foetus is outside the field of direct radia-
tion during cardiac procedures. Even though the risks are
small, radiation exposure should be avoided when possible.
However, if a procedure is absolutely necessary and there are
no alternatives, it should not be withheld and the mother can
be reassured. Radiation doses to the foetus should be kept as
low aspossible. Thiscan beachievedby minimising radiation
time. Therefore procedures should be performed by experi-
enced cardiologists. Abdominal shielding is recommended,
although this lowers the dose to the foetus by only 2%. Direct
radiation of the abdominal region should be avoided as much
as possible. The best period to perform invasive procedures is
the beginning of the second trimester, when organogenesis is
complete but the uterus is still small [2].
Iodine-containing contrast agents have been studied in
animals and did not appear to be teratogenic. There is,
however, a concern for neonatal hypothyroidism, therefore
their use should be minimised [16].
Summary and conclusions
Cardiac surgery is sometimes unavoidable during preg-
nancy. Mortality risk for the mother is 6% and is
comparable to that outside pregnancy. Foetal mortality
risk is however 14–33% and there is considerable foetal
morbidity. Therefore, when thef o e t u si sv i a b l e ,c a e s a r -
ean delivery before cardiac surgery should be consid-
ered. When this is not possible, cardiopulmonary bypass
should be adapted to meet the needs for adequate
Neth Heart J (2012) 20:125–128 127uteroplacental perfusion and to minimise the inducing of
uterine contractions. Percutaneous intervention, mostly
mitral balloon valvuloplasty and coronary angioplasty,
exposes the foetus to radiation. The procedures should
only be carried out when absolutely necessary, but the
radiation dose associated with these interventions is not
likely to cause harm to the foetus.
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